arrow&v
arrow&v
arrow&v
Title
Disease Type
Location
SolidTumor
Description
RegulatoryLink
MR2021.07
Solid Tumor
San Antonio, TX; Salt Lake City, UT
A Phase 1a/1b Study of LY3537982 Administered to Patients with Advanced Solid Tumors with KRAS G12C Mutation
https://clinicaltrials.gov/ct2/show/NCT04956640?term=LOXO-RAS-20001&draw=2&rank=1
MR2021.08
Solid Tumor
Grand Rapids, MI; Salt Lake City, UT
A Phase I, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03355066?term=SM08502-ONC-01&draw=2&rank=1
MR2021.10
Solid Tumor
San Antonio, TX; Grand Rapids, MI; Salt Lake City, UT
A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination with Anticancer Therapies in Subjects with Solid Malignancies
https://clinicaltrials.gov/ct2/show/NCT05006794?term=GS-US-467-5643&draw=2&rank=1
MR2020.02
Prostate
Salt Lake City, UT
An open-label, randomized study to assess the relative bioavailability (BA) and bioequivalence (BE) of fixed-dose combination (FDC) formulations of niraparib plus abiraterone acetate (AA) compared to niraparib and AA co-administered as single agents in men with prostate cancer
https://clinicaltrials.gov/ct2/show/NCT04577833?term=67652000PCR1001&draw=2&rank=1
MR2020.06
NSCLC, Solid Tumor
Salt Lake City, UT
Phase 1/2 dose escalation and expansion study evaluating MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors
https://clinicaltrials.gov/ct2/show/NCT04868877?term=MCLA-129-CL01&draw=2&rank=1
MR2021.03
Solid Tumors
Salt Lake City, UT
A Phase 1, 2-Part Study to Evaluate the Effect of Food on Pharmacokinetics of Pelabresib (CPI-0610) and the Effect of Pelabresib on QTc in Patients with Advanced Malignancies
http://Not posting available
MR2020.05
Solid Tumors
San Antonio, TX; Salt Lake City, UT
A Phase 1/1B Study to Evaluate the Safety and Tolerability of AB308 in Combination with AB122 in Participants with Advanced Malignancies
https://clinicaltrials.gov/ct2/show/NCT04772989?term=ARC-12&draw=2&rank=1
MR2020.03
Solid Tumors
Salt Lake City, UT
A Phase 1b/2 Open-Label Study of the Efficacy and Safety of Etigilimab (MPH313) Administered in Combination with Nivolumab to Subjects with Locally Advanced or Metastatic Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04761198?term=MPH313-1-02&draw=1&rank=1
SA2019.33
Solid Tumor
San Antonio, TX
A Phase 1, Open-Label, Dose-Escalation, and Cohort Expansion First‑in‑Human Study of the Safety, Tolerability, Pharmacokinetics, and Activity of FS120, an OX40/CD137 Bispecific Antibody, in Subjects with Advanced Malignancies
https://clinicaltrials.gov/ct2/show/NCT04648202?term=FS120-19101&draw=2&rank=1
MW2018.16
Solid Tumor
San Antonio, TX; Grand Rapids, MI
An Open-Label, Randomized-Sequence, Multicenter, Single Crossover Study to Assess the Relative Bioavailability and Bioequivalence Of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03329001?term=3000-01-004&rank=1
SA2017.29
Solid Tumor
San Antonio, TX; Grand Rapids, MI
An Open-Label, Randomized-Sequence, Multicenter, Single Crossover Study to Assess the Relative Bioavailability and Bioequivalence Of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03329001?term=3000-01-004&rank=1
MW2015.04
Solid Tumor
San Antonio, TX Grand Rapids, MI
Pending
A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chemotherapy in Subjects with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT02720068?term=MK-4280-001&rank=1
MW2016.15
Solid Tumor
San Antonio, TX Grand Rapids, MI
A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies
https://clinicaltrials.gov/ct2/show/NCT03005782?term=R3767-ONC-1613&rank=1
MW2016.19
Solid Tumor; Epithelial Malignancies
Grand Rapids, MI
A Phase 1a/2a Cohort Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of AVID100, an Anti-Human Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Linked to the Maytansinoid DM1, in Patients with Advanced or Metastatic Solid Tumors of Epithelial Origin
https://clinicaltrials.gov/ct2/show/NCT03094169?term=AVID100-01&rank=1
MW2016.22
Solid Tumor; Lymphoma
Grand Rapids, MI
A Phase 1, Dose Escalation Study of ALX148 in Patients with Advanced Solid Tumors and Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03013218?term=AT148001&rank=1
MW2016.27
Solid Tumor
Grand Rapids, MI
A Phase Ib Study to Evaluate the Safety and Tolerability of MK-8353 in combination with Pembrolizumab in Patients with Advanced Malignancies
https://clinicaltrials.gov/ct2/show/NCT02972034?term=MK-8353-013&rank=1
MW2017.01
Solid Tumor
Grand Rapids, MI Madrid, Spain
A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)
https://clinicaltrials.gov/ct2/show/NCT03157128?term=LOXO-RET-17001&rank=1
MW2017.04
Solid Tumor
Grand Rapids, MI Madrid, Spain
A Phase 1b Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03150810?term=BGB-290-103&rank=1
MW2017.05
Non-Small Cell Lung Cancer (NSCLC); Solid Tumor
San Antonio, TX Grand Rapids, MI
APG-1252 is a small molecule dual inhibitor of Bcl-2 and Bcl-xL proteins being developed as therapy for small cell lung cancer or other advanced solid tumors. In this study, APG-1252 will be given as intravenous infusion once a week or twice a week.
https://clinicaltrials.gov/ct2/show/NCT03080311?term=APG-1252-US-001&rank=1
MW2017.10
Solid Tumor; Lymphoma
Grand Rapids, MI
A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym021 (Anti-PD-1) as Monotherapy and in Combination with either Sym022 (Anti-LAG-3) or Sym023 (Anti-TIM-3) in Patients with Advanced Solid Tumor Malignancies or Lymphomas
https://clinicaltrials.gov/ct2/show/NCT03311412?term=Sym021-01&rank=1
MW2017.13
Solid Tumor; Hematologic
San Antonio, TX Grand Rapids, MI
APG-1387 for injection is a bivalent small-molecule IAP antagonist for subjects with advanced solid tumors (including breast, ovarian, colon, pancreatic, NSCLC). In this study, APG-1387 will be given as an intravenous infusion once a week alone or in combination with pembrolizumab
https://clinicaltrials.gov/ct2/show/NCT03386526?term=APG-1387-US-001&draw=2&rank=1
MW2018.04
Solid Tumor; Lymphoma
Grand Rapids, MI
An open-label, multicenter, first-in-man dose-escalation Phase 1 study of INBRX-105 in patients with locally advanced or metastatic solid tumors including Hodgkin and Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03809624?term=Ph1+INBRX-105&rank=1
MW2018.05
Solid Tumor, Sarcomas
Grand Rapids, MI
An open-label, multicenter, first-in-man dose-escalation Phase 1 study of INBRX-109 in patients with locally advanced or metastatic solid tumors and sarcomas.
https://clinicaltrials.gov/ct2/show/NCT03715933?term=Ph1+INBRX-109&rank=1
MW2018.11
Solid Tumor
San Antonio, TX Grand Rapids, MI
MK-5618 is a MEK1 and MEK2 inhibitor for subjects with advanced metastatic solid tumors.  In this study, MK-5618 will be given by mouth twice a day in combination with pembrolizumab given as and intravenous infusion every 3 weeks.
https://clinicaltrials.gov/ct2/show/NCT03833427?term=MK-5618-001&rank=1
MW2018.15
Solid Tumor
Grand Rapids, MI
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti–B7-H3 Antibody Drug Conjugate) Alone and in Combination with MGA012 (Anti–PD-1 Antibody) in Patients with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03729596?term=CP-MGC018-01&rank=1
MW2018.17
Solid Tumor
San Antonio, TX Grand Rapids, MI
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of CPI-100 via Intravenous Infusion in Patients with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03781362?term=CPI-CL18-001&rank=1
MW2018.19
Solid Tumor
Grand Rapids, MI
A Phase 1 Cohort Dose-Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients with Advanced or Metastatic Solid Tumor Malignancies
https://clinicaltrials.gov/ct2/show/NCT03834662?term=AVID200-03&rank=1
MW2018.21
Neoplasms
Grand Rapids, MI
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients with Unresectable or Metastatic Neoplasms
https://clinicaltrials.gov/ct2/show/NCT03761017?term=CP-MGD019-01&rank=1
MW2018.22
Solid Tumor
San Antonio, TX Grand Rapids, MI
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03845166?term=XL092-001&rank=1
MW2018.24
Solid Tumor; Lymphoma
San Antonio, TX Grand Rapids, MI
IBI188 is a CD47 inhibitor for subjects with advanced malignant tumors and lymphomas.  In this study, IBI188 will be given by intravenous infusion once a week.
https://clinicaltrials.gov/ct2/show/NCT03763149?term=CIBI188A102&rank=1
MW2019.01
Solid Tumor
San Antonio, TX Grand Rapids, MI
A Phase 1a/1b Study of COM701 as Monotherapy and In Combination with an Anti-PD-1 Antibody in Subjects with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03667716?term=CPG-01-001&rank=1
MW2019.06
Solid Tumor
Grand Rapids, MI
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of CPI-200 via Intravenous Infusion in Patients with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03953742?term=CPI-200CL01&rank=1
MW2019.07
Solid Tumor
San Antonio, TX Grand Rapids, MI
A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination with Other Therapy in Patients with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04104776?term=0209-01&draw=2&rank=1
MW2019.08
Solid Tumor
Grand Rapids, MI
A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201)
N/A - no posting available 
MW2019.09
Solid Tumor
Grand Rapids, MI
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-106 in Subjects with Locally Advanced or Metastatic Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04198766?term=Ph1+INBRX-106&draw=2&rank=1
MW2019.10
Solid Tumor
Grand Rapids, MI
A Phase 1/2 First-in-human Study of BMS-986258 Alone and in Combination with Nivolumab in Advanced Malignant Tumors
https://clinicaltrials.gov/ct2/show/NCT03446040?term=CA031_002&draw=2&rank=1
MW2019.12
Solid Tumor
Grand Rapids, MI
An Open-Label Study of the Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04312282?term=ODO-TE-S101&draw=2&rank=1
MW2019.16
Solid Tumor
Grand Rapids, MI
A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable /Metastatic Solid Tumors who are refractory to Available Standard Therapies
https://clinicaltrials.gov/ct2/show/NCT04152499?term=KL264-01&draw=2&rank=1
MW2019.21
Solid Tumor
San Antonio, TX Grand Rapids, MI
A Phase 1 Study of SY-5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients with Select, Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04247126?term=SY-5609-101&draw=2&rank=1
MW2019.25
Solid Tumors; Urothelial Carcinoma
Grand Rapids, MI
A Phase 1, Open-Label, Dose-Escalation and Expansion Study of IK-175, an Oral Aryl Hydrocarbon Receptor (AHR) Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
https://clinicaltrials.gov/ct2/show/NCT04200963?term=IK175-001&draw=2&rank=1
MW2019.26
HER2-Expressing; Solid Tumor
San Antonio, TX Grand Rapids, MI
Phase 1 Study of BDC-1001 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced and HER2 Expressing Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04278144?term=BBI-20201001&draw=2&rank=1
MW2019.28
Solid Tumor
San Antonio, TX Grand Rapids, MI
A Phase 1 Study of the Safety and Tolerability of COM902 in Subjects with Advanced Malignancies
https://clinicaltrials.gov/ct2/show/NCT04354246?term=CPG-02-101&draw=2&rank=1
MW2019.30
Non-Small Cell Lung Cancer (NSCLC)
Grand Rapids, MI
An Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma
https://clinicaltrials.gov/ct2/show/NCT03696212?term=ARYS-002&draw=2&rank=1
MW2020.04
Solid Tumor
Grand Rapids, MI
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects with Selected Advanced Solid Tumor Malignancies
https://clinicaltrials.gov/ct2/show/NCT04092673?term=eFT226-0002&draw=2&rank=1
MW2020.12
Solid Tumor
San Antonio, TX Grand Rapids, MI
A Phase 1a/1b Open-label, Dose-Escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination with Pembrolizumab in Subjects with Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04344795?term=TPST-1495-001&draw=2&rank=1
SA2019.28
Breast
San Antonio, TX
Phase 1/1b Multicenter, Open-Label, First-in-Human Dose Escalation and Dose Expansion Study to Assess Safety and Tolerability of Orally Administered PMD-026 in Patients with Metastatic Breast Cancer with Expansion in Metastatic Triple Negative Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT04115306?term=PMD-026-1-001&draw=2&rank=1
SA2019.30
Ovarian, Breast, CRC, Lung Cancer
San Antonio, TX Grand Rapids, MI
A Phase 1 Study of SY-5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients with Select, Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04247126?term=SY-5609-101&draw=2&rank=1
SA2019.32
HER2-Expressing; Solid Tumor
San Antonio, TX Grand Rapids, MI
Phase 1 Study of BDC-1001 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced and HER2-Expressing Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04278144?term=BBI-20201001&draw=2&rank=1
SA2019.34
Solid Tumor
San Antonio, TX
A Phase 1 Open-label Dose Escalation Study of BDB001 in Combination with Atezolizumab in Subjects with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04196530?term=BDB001-102&draw=2&rank=1
SA2019.38
Solid Tumor
San Antonio, TX
A Phase 1 Study of SGN-B6A in Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04389632?term=SGNB6A-001&draw=2&rank=1
SA2019.39
Solid Tumor
San Antonio, TX
A Phase 1 Study of SRF388 in Patients with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04374877?term=SRF388-101&draw=2&rank=1
SA2019.42
Solid Tumor
San Antonio, TX Grand Rapids, MI
A Phase 1a/1b Open-label, Dose-Escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination with Pembrolizumab in Subjects with Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04344795?term=TPST-1495-001&draw=2&rank=1
SA2020.03
Solid Tumor
San Antonio, TX Grand Rapids, MI
A Phase 1 Study of the Saftery and Tolerability of COM902 in Subjects with Advanced Malignancies
https://clinicaltrials.gov/ct2/show/NCT04354246?term=CPG-02-101&draw=2&rank=1
SA2014.22
Solid Tumor
San Antonio, TX
Adenocystic
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies
https://clinicaltrials.gov/ct2/show/NCT02393248 term=INCB+54828-101&rank=1
SA2015.33
Solid Tumor; Non-Hodgkin Lymphoma
San Antonio, TX
Ampulla of Vader
A phase I, open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK3326595 in subjects with solid tumors and non-Hodgkin's lymphoma
https://clinicaltrials.gov/ct2/show/NCT02783300?term=204653&rank=1
SA2015.41
Solid Tumor
San Antonio, TX
Appendix
A Phase 1/2 Dose-escalation of USL311 as Single Agent and in Combination with Lomustine (CCNU) in Subjects with Advanced Solid Tumors, with Subsequent Single Agent and Combination Phase 2 Cohorts for Subjects with Relapsed/Recurrent Glioblastoma Multiforme (GBM)
https://clinicaltrials.gov/ct2/show/NCT02765165?term=P311-201&rank=1
SA2015.51
Solid Tumor
San Antonio, TX Grand Rapids, MI
Basal Cell
A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chemotherapy in Subjects with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT02720068?term=MK-4280-001&rank=1
SA2016.06
HER2-Expressing; Breast, Esophageal, Lung, Cervical, Endometrial; Ovarian
San Antonio, TX
Bladder
Phase 1 trial of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers
https://clinicaltrials.gov/ct2/show/NCT02892123?term=ZWI-ZW25-101&rank=1
SA2016.24
Solid Tumor
San Antonio, TX; Madrid, Spain
Breast
ABBV-621 is a second generation tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor agonist that targets death receptor 4 and death receptor 5 for subjects with advanced solid tumors. In this study, ABBV-621 will be given by intravenous infusion once weekly alone or in combination with other chemotherapies.
https://clinicaltrials.gov/ct2/show/NCT03082209?term=M15-913&rank=1
SA2016.26
Solid Tumor
San Antonio, TX Grand Rapids, MI
Carcinoid
A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies
https://clinicaltrials.gov/ct2/show/NCT03005782?term=R3767-ONC-1613&rank=1
SA2016.34
Solid Tumor
San Antonio, TX
Cervical
A Phase 1, Dose-Escalation and Expansion Trial of PT2977, a HIF-2? Inhinitor, in Patients with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT02974738?term=PT2977-101&rank=1
SA2016.41
Solid Tumor
San Antonio, TX
Cholangiocarcinoma
A Phase 1 Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT02964013?term=MK-7684-001&rank=1
SA2016.52
Solid Tumor
San Antonio, TX
Chordoma
A Phase 1b/2a Dose-escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects with Advanced Malignancies
https://clinicaltrials.gov/ct2/show/NCT03297424?term=PLX124-01&rank=1
SA2017.03
Solid Tumor
San Antonio, TX
Colon
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects with Locally Advanced or Metastatic Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03071757?term=M16-074&rank=1
SA2017.09
Solid Tumor
San Antonio, TX
Cutaneous Squamous-Cell Carcinoma (CSCC)
A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients with HER2-Positive Advanced or Metastatic Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03330561?term=PRS-343-PCS_04_16&rank=1
SA2017.12
Solid Tumor
San Antonio, TX
Endometrial
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an anti-LAG-3 Monoclonal Antibody, alone and in combination with an anti-PD-1 in Patients with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03250832?term=4040-01-001&rank=1
SA2017.18
Solid Tumor
San Antonio, TX
Esophageal
A Phase 1 Open-label Dose Escalation Study of BDB001 as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03486301?term=BDB001-101&rank=1
SA2017.25
Solid Tumor
San Antonio, TX
Gall Bladder
A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-Tumor Activity of ABBV-321 in Subjects with Advanced Solid Tumors Associated with Overexpression of the Epidermal Growth Factor Receptor (EGFR)
https://clinicaltrials.gov/ct2/show/NCT03234712?term=M16-438&rank=1
SA2017.26
Solid Tumor
San Antonio, TX
Gastric
A Phase 1 Study Evaluating the Safety, Pharmacology, and Preliminary Activity of VT1021 in Patients with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03364400?term=VT1021-01&rank=1
SA2017.28
Solid Tumor
San Antonio, TX
Glioblastoma (GBM)
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03314935?term=INCB+01158-203&rank=1
SA2017.32
Solid Tumor
San Antonio, TX
Gastrointestinal Stromal Tumors (GIST)
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b
N/A - no posting available
SA2017.35
Solid Tumor; Ovarian Carcinoma
San Antonio, TX
Glioblastoma
APG-1387 for injection is a bivalent small-molecule IAP antagonist for subjects with advanced solid tumors (including breast, ovarian, colon, pancreatic, NSCLC). In this study, APG-1387 will be given as an intravenous infusion once a week alone or in combination with pembrolizumab
https://clinicaltrials.gov/ct2/show/NCT03386526?term=APG-1387-US-001&rank=1
SA2017.39
Solid Tumor
San Antonio, TX
Hepatocellular Carcinoma (HCC)
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03520075?term=ASTX029-01&rank=1
SA2017.41
Solid Tumor
San Antonio, TX
Head and Neck
FS118 is LAG-3/PD-Ll bispecific antibody for subjects with advanced malignancies.� In this study, FS118 will be given by intravenous infusion once a week.
https://clinicaltrials.gov/ct2/show/NCT03440437?term=FS118-17101&rank=1
SA2018.01
Solid Tumor
San Antonio, TX
Hepatocellular
A Phase 1b Study of ASP1948, Targeting an Immune Modulatory Receptor, as a Single Agent and in Combination with Nivolumab in Subjects with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03565445?term=1948-CL-0101&rank=1
SA2018.02
Solid Tumor
San Antonio, TX
Lung
MK-4830 is an ILT4 antagonist for subjects with advanced solid tumors.� In this study, MK-4830 will be given by intravenous infusion once every 3 weeks in combination with pembrolizumab
https://clinicaltrials.gov/ct2/show/NCT03564691?term=MK-4830-001&rank=1
SA2018.06
Solid Tumor
San Antonio, TX Grand Rapids, MI
Lymphoma
A Phase 1a/1b Study of COM701 as Monotherapy and In Combination with an Anti-PD1 Antibody in Subjects with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03667716?term=CPG-01-001&rank=1
SA2018.08
Solid Tumor
San Antonio, TX
Melanoma
An open-label, Phase 1, first-in-human, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics and tumor response profile of the ILDR2 function-blocking antibody BAY 1905254 in patients with advanced solid tumors
https://clinicaltrials.gov/ct2/show/NCT03666273?term=18789&rank=1
SA2018.11
Solid Tumor
San Antonio, TX
Meningiom
INCMGA00012 is a monoclonal antibody that recognizes human PD-1. In this study, subjects with advanced solid tumors will receive INCMGA00012 by intravenous infusion every 4 weeks in combination with Epacadostat tablets by mouth twice a day or INCB050465 tablets by mouth once a day.
https://clinicaltrials.gov/ct2/show/NCT03589651?term=INCMGA+0012-102&rank=1
SA2018.12
Non-Small Cell Lung Cancer (NSCLC); Colorectal; Pancreatic
San Antonio, TX
Merckel Cell
A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination with Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma
https://clinicaltrials.gov/ct2/show/NCT03948763?term=V941-001&rank=1
SA2018.13
Solid Tumor
San Antonio, TX
Mesothelioma
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
https://clinicaltrials.gov/ct2/show/NCT03785249?term=849-001&rank=1
SA2018.17
Solid Tumor
San Antonio, TX
Non-Hodgkin Lymphoma (NHL)
A Phase I-II, First-in-Human Study of A166 in Patients with Locally Advanced/Metastatic Solid Tumors which are Human Epidermal Growth Factor Receptor 2 (HER2)-Positive who did not Respond or Stopped Responding to Approved Therapies and Patients with HER2 Positive (by ISH or NGS) or Low Expressing (by IHC) Solid Tumors who did not Respond or Stopped Responding to Approved Therapies
N/A - no posting available
SA2018.19
Solid Tumor
San Antonio, TX
Ovarian
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
https://clinicaltrials.gov/ct2/show/NCT03486873?term=MK-3475-587&rank=1
SA2018.22
Solid Tumor
San Antonio, TX
Pancreatic
ADCT-301 (Camidanlumab tesirine) is an antibody-drug conjugate targeting human CD25 in subjects with selected advanced solid tumors. In this study, Camidanlumab tesirine will be given by intravenous infusion once every 3 weeks.�
https://clinicaltrials.gov/ct2/show/NCT03621982?term=ADCT-301-103&rank=1
SA2018.23
Solid Tumor
San Antonio, TX Grand Rapids, MI
Perotoneal
Phase 1 First in Human Study of Programmed Cell Death Receptor-1 (PD-1) Inhibitor Monoclonal Antibody (mAb) JTX-4014 in Adult Subjects with Advanced Refractory Solid Tumor Malignancies
https://clinicaltrials.gov/ct2/show/NCT03790488?term=JTX-4014-101&rank=1
SA2018.25
Solid Tumor; Hematologic
San Antonio, TX
Prostate
A Phase 1, Open-Label, Dose Finding Study of CC-95251, A Monoclonal Antibody Directed Against SIRP?, Alonf and in Cobmination with Cetuximab or Rituximab in Subjects with Adavanced Solid and Hematologic Cancers
https://clinicaltrials.gov/ct2/show/NCT03783403?term=CC-95251-ST-001&rank=1
SA2018.27
Solid Tumor
San Antonio, TX
Rectal
A Phase 1 Study of ASP1951 in Subjects with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03799003?term=1951-CL-0101&rank=1
SA2018.29
Solid Tumor
San Antonio, TX Grand Rapids, MI
Renal
MK-5618 is a MEK1 and MEK2 inhibitor for subjects with advanced metastatic solid tumors.� In this study, MK-5618 will be given by mouth twice a day in combination with pembrolizumab given as and intravenous infusion every 3 weeks.
https://clinicaltrials.gov/ct2/show/NCT03833427?term=MK-5618-001&rank=1
SA2018.31
Solid Tumors
San Antonio, TX Grand Rapids, MI
Sarcoma
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid�Tumors
https://clinicaltrials.gov/ct2/show/NCT03845166?term=XL092-001&rank=1
SA2018.32
Solid Tumor
San Antonio, TX
Small Cell Lung Cancer (SCLC)
An open-label, Phase 1, first-in-human, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics and tumor response profile of the Aryl Hydrocarbon Receptor inhibitor (AhRi) BAY 2416964 alone and in combination with an anti PD-(L)1 inhibitor in patients with advanced solid tumors
https://clinicaltrials.gov/ct2/show/NCT04069026?term=20201&draw=2&rank=1
SA2018.34
Solid Tumor
San Antonio, TX
Testicular
A Phase 1b/2 open label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with the PARP inhibitor Talazoparib in Patients with Advanced or Metastatic Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03875313?term=CX-839-011&rank=1
SA2018.36
Solid Tumor
San Antonio, TX Grand Rapids, MI
Thyroid
Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of CPI-100 via Intravenous Infusion in Patients with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03781362?term=CPI-CL18-001&rank=1
SA2018.40
Solid Tumor; Lymphoma
San Antonio, TX Grand Rapids, MI
Tonsil
IBI188 is a CD47 inhibitor for subjects with advanced malignant tumors and lymphomas.� In this study, IBI188 will be given by intravenous infusion once a week.
https://clinicaltrials.gov/ct2/show/NCT03763149?term=CIBI188A102&rank=1
SA2019.01
Solid Tumor
San Antonio, TX
Unknown Primary
A First-in-Human, Multicenter, Open-label, Phase 1 Dose-Escalation Study of FCN-437c in Patients with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03951116?term=FCN-437c-001&rank=1
SA2019.04
Solid Tumor
San Antonio, TX
Urothelial
A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants with Advanced Malignancies
https://clinicaltrials.gov/ct2/show/NCT03628677?term=AB154CSP0001&rank=1
SA2019.08
Solid Tumor
San Antonio, TX
Uterine
A Phase 1b/2, Open label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with the CDK4/6 Inhibitor Palbociclib in Patients with Advanced or Metastatic Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03965845?term=CX-839-012&rank=1
SA2019.12
Breast
San Antonio, TX
Vulvar
LY3295668 is a highly selective orally bioavailable and reversible AurA inhibitor for subjects with metastatic breast cancer.� In this study, LY3295668 will be given by mouth twice a day with other endocrine therapy.
https://clinicaltrials.gov/ct2/show/NCT03955939?term=J1O-MC-JZHC&rank=1
SA2019.17
Solid Tumor
San Antonio, TX
GB1275 is CD11b agonist for subjects with metastatic solid tumors.� In this first-in-human study, GB1275 will be taken by mouth every day alone or in combination with pembrolizumab or nab-paclitaxel and gemcitabine in selected tumor types.
https://clinicaltrials.gov/ct2/show/NCT04060342?term=GB1275-1101&draw=2&rank=1
SA2019.18
Solid Tumor
San Antonio, TX
A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Locally Advanced or Metastatic Cancer
https://clinicaltrials.gov/ct2/show/NCT04130516?term=LNS-101&draw=2&rank=1
SA2019.20
Solid Tumor
San Antonio, TX Grand Rapids, MI
A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination with Other Therapy in Patients with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04104776?term=0209-01&draw=2&rank=1
SA2019.23
Solid Tumor
San Antonio, TX
A Phase 1 Study of SRF617 in Patients with Advanced Solid Tumors or Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04336098?term=SRF617-101&draw=2&rank=1
SA2019.25
Breast
San Antonio, TX
Phase 2a Study of ZW25 in Combination with Palbociclib Plus Fulvestrant
https://clinicaltrials.gov/ct2/show/NCT04224272?term=ZWI-ZW25-202&draw=2&rank=1
SA2019.27
Breast
San Antonio, TX
A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Abemaciclib to Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
https://clinicaltrials.gov/ct2/show/NCT04188548?term=J2J-MC-JZLA&draw=2&rank=1